Humanigen Announces Completion of Enrollment in Phase I Study of Ifabotuzumab in Glioblastoma Multiforme

Humanigen, Inc. announced completing enrollment in its Phase I bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme. Ifabotuzumab, or ifab, is the company’s proprietary anti-EphA3 monoclonal antibody.